The Melbourne Symphony Orchestra Selects Brightcove to Power New Digital Platform
17.5.2021 02:00:00 EEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the global leader in video for business, today announced that the Melbourne Symphony Orchestra (MSO) is using Brightcove to power its new digital platform MSO.LIVE to cast the Orchestra’s 2021 season in Australia and around the world.
“Brightcove’s technology delivers a polished interface with exceptional quality of video and audio across multiple devices, to ensure we can deliver easily accessible, world-class digital experiences to all audiences,” said Sophie Galaise, Managing Director of the Melbourne Symphony Orchestra.
The MSO is a world-class orchestra with global credibility in providing enriching music experiences to audiences. MSO.LIVE offers 24-hour entertainment on-demand, live, and pre-recorded, delivering accessible and premium content as an alternative to traditional, in-person orchestral experiences. The MSO.LIVE experience is accessible, offering MSO concerts, family programming, and special events and performances from around the world.
A key driver for implementing Brightcove’s online video platform is to make performance experiences easily accessible and affordable to a wider audience, including those who are unable to attend in-person concerts.
The MSO’s main focus is to optimise its content delivery experience to retain existing orchestral music fans and attract new audiences from around the world to the MSO.LIVE platform. New performances are released monthly, and MSO.LIVE members are able to view content across devices and connected TVs.
Using Brightcove, MSO.LIVE demonstrates innovation within the Australian arts community by offering a contemporary content library personalised to audience preferences. “Among other criteria, we selected Brightcove as their local team of experts had the capabilities to integrate customer data with our CRM system,” said Ms. Galaise.
MSO.LIVE offers a range of traditional and contemporary content from both the MSO and other world-class orchestras from around the world, such as the Berliner Philharmoniker and Royal Concertgebouw Orchestra.
MSO.LIVE is priced at $15 per month or $144 per year for an annual subscription, or audiences can subscribe to a one-month pass or pay-per-view access. MSO.LIVE also offers a selection of free content, including programs for kids, audio, and more. View MSO.LIVE here.
“Our partnership with the Melbourne Symphony Orchestra demonstrates the power that video provides to the entertainment and music industry,” said Jennifer Smith, Chief Marketing Officer, Brightcove. “Brands in the Arts and Entertainment sector are embracing the hybrid model to allow them to grow their audiences to engage both in-person and online viewers. 2020 drove the urgency to pivot to new digital video experiences, and businesses are now embracing this as a long-term growth strategy. MSO.LIVE takes the orchestral experience to the next level and cements the MSO as a leader when it comes to the future of live performances,” said Smith.
As part of a longer-term strategy, the introduction of MSO.LIVE will help demonstrate Australia’s unique culture and celebrate the diverse talents of its local artists with the rest of the world.
About Melbourne Symphony Orchestra
Each year, the MSO engages with more than 5 million people through live concerts, TV, radio and online broadcasts, international and regional tours, recordings and education programs.
The MSO is a vital presence, both onstage and in the community, in cultivating classical music in Australia. Internationally acclaimed, the Orchestra nurtures strong cultural partnerships throughout South-East Asia. The MSO is the only Australian orchestra partnered with UNITEL, the world’s leading distributor of classical music programs for film, television and video.
The MSO regularly attracts great artists from around the globe, including Anne-Sophie Mutter, Lang Lang, Renée Fleming and Nick Cave, while bringing Melbourne’s finest musicians to the world through tours to China, Indonesia, Europe and the United States.
The nation’s first professional orchestra, the Melbourne Symphony Orchestra has been the sound of the city of Melbourne since 1906. www.mso.com.au.
About Brightcove Inc.
When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organisations in more than 70 countries across the globe to touch audiences in bold and innovative ways.
Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business™
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210516005011/en/
Contact information
Brightcove Press
Meredith Duhaime
Senior Public Relations Manager
Brightcove | (603) 785-8518
mduhaime@brightcove.com
Livia Budisetio
Account Executive
LEWIS Global Communications | (61) 411 208 431
brightcoveANZ@teamlewis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
